Nimenrix Vaccine. Previous anaphylactic reaction to any. Cdc recommends meningococcal vaccines for preteens, teens, and certain other people.
All preteens at 11 to 12 years old. Infants and children aged 9 months to 2 years can receive any of the 3 menacwy. From age 1 year and above, nimenrix can be.
Ad Visit The Consumer Website To Learn About A Vaccine Option.
Nimenrix is a vaccine used to help prevent meningococcal disease, caused by four types of neisseria meningitidis bacteria (types a, c, w and y). Study to evaluate the safety and immunogenicity of nimenrix (registered) in healthy infants, given at 3 and 12 months of age. The menzb™ vaccine used in new zealand between 2004 and 2011 was designed to target a specific type of meningococcal group b bacteria that caused a prolonged epidemic here in.
In April 2012 Nimenrix Was Approved As The.
Product monograph (download pdf, 403kb) patient information (download pdf,. Previous anaphylactic reaction to any. From age 1 year and above, nimenrix can be.
Nimenrix Is A Vaccine Used To Help Prevent Meningococcal Disease, Caused By Four Types Of Neisseria Meningitidis Bacteria (Types A, C, W And Y).
Since protection wanes, cdc recommends a booster dose at age 16 years. Learn more about a vaccine option on the site. Nimenrix works by causing your body to.
All Teens At 16 Years Old.
All preteens at 11 to 12 years old. The booster dose provides protection during the ages when adolescents are at highest risk of meningococcal. Nimenrix works by causing your body to.
Nimenrix May Be Given As A Booster Dose To Individuals Who Have Previously Received Primary Vaccination With Nimenrix Or Other Conjugated Or Plain Polysaccharide Meningococcal.
Infants and children aged 9 months to 2 years can receive any of the 3 menacwy. Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium. Cdc recommends meningococcal vaccines for preteens, teens, and certain other people.